INTEGRAGEN (ALINT.PA) Stock Price, Forecast & Analysis

Europe • Euronext Paris • EPA:ALINT • FR0010908723

0.1515 EUR
0 (-0.33%)
Last: Feb 2, 2026, 07:00 PM

ALINT.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap1.02M
Revenue(TTM)6.69M
Net Income(TTM)-1.55M
Shares6.73M
Float2.18M
52 Week High0.73
52 Week Low0.12
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.23
PEN/A
Fwd PEN/A
Earnings (Next)04-27
IPO2010-06-18
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
ALINT.PA short term performance overview.The bars show the price performance of ALINT.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40

ALINT.PA long term performance overview.The bars show the price performance of ALINT.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALINT.PA is 0.1515 EUR. In the past month the price increased by 11.4%. In the past year, price decreased by -71.42%.

INTEGRAGEN / ALINT Daily stock chart

ALINT.PA Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to ALINT.PA. When comparing the yearly performance of all stocks, ALINT.PA is a bad performer in the overall market: 94.54% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ALINT.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ALINT.PA. The financial health of ALINT.PA is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALINT.PA Financial Highlights

Over the last trailing twelve months ALINT.PA reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS decreased by -2200% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -42.94%
ROE -442.86%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-950%
Sales Q2Q%-43.98%
EPS 1Y (TTM)-2200%
Revenue 1Y (TTM)-39.29%

ALINT.PA Forecast & Estimates


Analysts
Analysts86.67
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

ALINT.PA Ownership

Ownership
Inst OwnersN/A
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

ALINT.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
1AE.DE ARGENX SE 68 44.18B
ARGX.BR ARGENX SE 67.58 43.91B
22UA.DE BIONTECH SE-ADR N/A 22.29B
ABVX.PA ABIVAX SA N/A 7.44B
2X1.DE ABIVAX SA N/A 7.33B
GLPG.AS GALAPAGOS NV N/A 1.89B
GXE.DE GALAPAGOS NV N/A 1.90B
IVA.PA INVENTIVA SA N/A 1.00B
6IV.DE INVENTIVA SA N/A 953.87M
NANO.PA NANOBIOTIX N/A 869.05M
PHIL.MI PHILOGEN SPA 18.86 628.66M
FYB.DE FORMYCON AG N/A 405.53M

Related stock screener links

About ALINT.PA

Company Profile

ALINT logo image IntegraGen SA engages in the development of genetic biomarkers. The company is headquartered in Evry, Ile-De-France and currently employs 39 full-time employees. The company went IPO on 2010-06-18. The company researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. The company uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). The company also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The firm also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.

Company Info

INTEGRAGEN

Genopole Campus 1 - Genavenir 8 5 Rue Henri Desbrueres

Evry ILE-DE-FRANCE FR

Employees: 39

ALINT Company Website

ALINT Investor Relations

Phone: 33160910900

INTEGRAGEN / ALINT.PA FAQ

What does ALINT do?

IntegraGen SA engages in the development of genetic biomarkers. The company is headquartered in Evry, Ile-De-France and currently employs 39 full-time employees. The company went IPO on 2010-06-18. The company researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. The company uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). The company also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The firm also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.


Can you provide the latest stock price for INTEGRAGEN?

The current stock price of ALINT.PA is 0.1515 EUR. The price decreased by -0.33% in the last trading session.


Does INTEGRAGEN pay dividends?

ALINT.PA does not pay a dividend.


What is the ChartMill technical and fundamental rating of ALINT stock?

ALINT.PA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the next earnings date for ALINT stock?

INTEGRAGEN (ALINT.PA) will report earnings on 2026-04-27.